Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
Dermatol Clin. 2010 Jan;28(1):107-14. doi: 10.1016/j.det.2009.10.020.
Dystrophic epidermolysis bullosa (DEB) is relatively well understood. Potential therapies are in development. This article describes the pathogenesis and clinical features of DEB. It also describes therapeutic options and the future of molecular therapies.
营养不良型大疱性表皮松解症(DEB)的相关研究较为透彻,潜在疗法正在研发中。本文介绍了 DEB 的发病机制和临床特征,还描述了治疗选择和分子疗法的未来。